Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?

Xia, B. T.,Fu, B.,Wang, J.,Kim, Y.,Ahmad, S. A.,Dhar, V. K.,Levinsky, N. C.,Hanseman, D. J.,Habib, D. A.,Wilson, G. C.,Smith, M.,Olowokure, O. O.,Kharofa, J.,Al Humaid...; J Surg Oncol. 2017 Jan 21.

Results of the 2013-2015 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States.

Nabavizadeh, N.,Burt, L. M.,Mancini, B. R.,Morris, Z. S.,Walker, A. J.,Miller, S. M.,Bhavsar, S.,Mohindra, P.,Kim, M. B.,Kharofa, J.; Int. J. Radiat. Oncol. Biol. Phys.. 2016 Feb 09.

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Kharofa, J.,Tsai, S.,Kelly, T.,Wood, C.,George, B.,Ritch, P.,Wiebe, L.,Christians, K.,Evans, D. B.,Erickson, B.; Radiother Oncol. 2014 Dec 03.